A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.

Bill: 117-s-1508
Sponsor: full_name: Sen. Marshall, Roger [R-KS]
Introduced: 2021-04-29
Policy area: Health
Subjects: Drug safety, medical device, and laboratory regulation

Government information and archives

Health technology, devices, supplies

Licensing and registrations
Latest action: action_date: 2021-04-29
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2021-04-29
action_desc: Introduced in Senate
text: <p>This bill establishes that certain data and determinations from a request for emergency use authorization for a drug, biological product, or medical device may apply to later regulatory procedures for that product.</p> <p>Specifically, data generated to support a request for emergency use authorization may constitute valid scientific evidence to be considered for various later submissions to the Food and Drug Administration (FDA), including a request for market approval.</p> <p>Also, when granting emergency use authorization for a medical device, if the FDA determines that the device performs certain simple low-risk examinations, that determination shall apply to certain other regulatory submissions unless additional information contradicts that determination.</p>

tv_txt: II 117th CONGRESS 1st Session S. 1508 IN THE SENATE OF THE UNITED STATES April 29, 2021 Mr. Marshall (for himself, Ms. Smith , and Mr. Cassidy ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.

1. Using emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices (a) In general Data generated to support an authorization under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ) with respect to a drug, biological product, or device, and real world evidence relating to such drug, biological product, or device used pursuant to such authorization, may constitute valid scientific evidence, and shall be considered for purposes of— (1) reviewing submissions pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) and section 351 of the Public Health Service Act ( 42 U.S.C. 262 ); (2) reviewing submissions pursuant to sections 510(k), 513(f), and 515 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 21 U.S.C. 360(k), 360c(f), or 360e); and (3) otherwise meeting the requirements of such Act and such section 351 of the Public Health Service Act. (b) Applicability of certain categorizations for premarket device review In the case of a device receiving an authorization under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ) for which the Secretary has determined, in accordance with subsection (m) of such section, that a laboratory examination or procedure associated with such device is deemed to be in the category of examinations and procedures described in section 353(d)(3) of the Public Health Service Act ( 42 U.S.C. 262 ), such determination shall apply with regard to a submission pursuant to section 510(k), 513(f), or 515 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 21 U.S.C. 360(k), 360c(f), or 360e) for such device, unless the Secretary (taking into account any applicable conditions specified pursuant to subsection (m)(2) of section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 )) identifies new information not included in the request for authorization that indicates that the criteria under section 353(d)(3) of the Public Health Service Act ( 42 U.S.C. 262 ) are not met. (c) Rule of construction Nothing in this section shall be construed as altering the review standards or otherwise affecting the requirements under section 505, 510(k), 513(f), or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 21 U.S.C. 355 , 360(k), 360c(f), or 360e) or under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) for the clearance or approval of a device, approval of a drug, or licensure of a biological product.